{"id":619913,"date":"2022-10-06T17:06:01","date_gmt":"2022-10-06T17:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=619913"},"modified":"2022-10-06T17:06:01","modified_gmt":"2022-10-06T17:06:01","slug":"plasma-fractionation-market-size-20222027-global-industry-forecast-share-trends-and-growth","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/plasma-fractionation-market-size-20222027-global-industry-forecast-share-trends-and-growth_619913.html","title":{"rendered":"Plasma Fractionation Market Size 2022-2027 | Global Industry Forecast, Share, Trends and Growth"},"content":{"rendered":"
\n
\"Plasma<\/a><\/div>\n
\n
Plasma Fractionation Market Size<\/div>\n<\/div>\n<\/div>\n
The global plasma fractionation market size reached US$ 22.37 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 33.11 Billion by 2027 exhibiting a growth rate (CAGR) of 6.30% during 2022-2027<\/div>\n

Plasma Fractionation Market Overview<\/strong><\/p>\n

The latest research study “Plasma Fractionation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global plasma fractionation market size reached US$ 22.37 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 33.11 Billion by 2027<\/a> exhibiting a growth rate (CAGR) of 6.30% during 2022-2027.<\/p>\n

Plasma fractionation represents the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or fractions by using numerous mechanical separation methods, such as depth filtration, centrifugation, precipitation, chromatography, etc. Presently, several advanced fractionation processes use alcohol concentrations, temperature, pH, etc., to extract specific therapeutic proteins. Furthermore, the introduction of in-process viral reduction treatments and increasing technological complexities have resulted in the development of new protein therapeutics as well as improved product purity and quality.<\/p>\n

Covid-19 Impact Analysis:<\/strong><\/p>\n

 <\/p>\n

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.<\/em><\/p>\n

Request a free sample brochure: https:\/\/www.imarcgroup.com\/plasma-fractionation-market\/requestsample<\/a><\/strong><\/p>\n

Plasma Fractionation Market<\/strong> Trends and Drivers: <\/strong><\/p>\n

The growing prevalence of congenital deficiencies, blood infections, immunologic and autoimmune disorders, etc., is primarily driving the plasma fractionation market. Additionally, the escalating demand for this processing with additional safety features, on account of the implementation of various stringent regulations and standard settings by government bodies across countries for quality assurance of biological products, is also catalyzing the market growth.<\/p>\n

Besides this, the rising investments in plasma production technology to improve efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins are acting as significant growth-inducing factors. Moreover, the widespread adoption of affordable viral inactivation processes that allow the utilization of local plasma resources safely is positively influencing the global market.<\/p>\n

Apart from this, the inflating need for improving yield and maintaining process economics is anticipated to fuel the plasma fractionation market over the forecasted period.<\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Plasma Fractionation Market Report Scope<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Report Coverage<\/strong><\/p>\n<\/td>\n

\n

Details<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Market size value in 2021<\/p>\n<\/td>\n

\n

US$ 22.37 Billion<\/p>\n<\/td>\n<\/tr>\n

\n

Market forecast in 2027<\/p>\n<\/td>\n

\n

US$ 33.11 Billion<\/p>\n<\/td>\n<\/tr>\n

\n

Growth Rate<\/p>\n<\/td>\n

\n

CAGR of 6.30% from 2022 to 2027<\/p>\n<\/td>\n<\/tr>\n

\n

Base year for estimation<\/p>\n<\/td>\n

\n

2021<\/p>\n<\/td>\n<\/tr>\n

\n

Historical data<\/p>\n<\/td>\n

\n

2016-2021<\/p>\n<\/td>\n<\/tr>\n

\n

Forecast period<\/p>\n<\/td>\n

\n

2022-2027<\/p>\n<\/td>\n<\/tr>\n

\n

Report coverage<\/p>\n<\/td>\n

\n

Revenue forecast, company ranking, competitive landscape, growth factors, and trends<\/p>\n<\/td>\n<\/tr>\n

\n

Segments covered<\/p>\n<\/td>\n

\n

Product, Sector, Application and End user<\/p>\n<\/td>\n<\/tr>\n

\n

Regional scope<\/p>\n<\/td>\n

\n

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa<\/p>\n<\/td>\n<\/tr>\n

\n

Key companies profiled<\/p>\n<\/td>\n

\n

ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.<\/p>\n<\/td>\n<\/tr>\n

\n

Market Dynamics<\/p>\n<\/td>\n

\n

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,<\/p>\n<\/td>\n<\/tr>\n

\n

Customization preview<\/p>\n<\/td>\n

\n

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Report Segmentation: <\/strong><\/p>\n

The report has been segmented the market into following categories:<\/strong><\/p>\n

Breakup by Product:<\/strong><\/p>\n